A Post Marketing Surveillance to assess the safety of GardasilÂ® in females of 9 to 45 years in routine clinical care - NA

MSD Pharmaceuticals PvtLtd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Subjects who provide voluntary written informed consent/ assent to participate in the study.
•Female subjects 9 to 45 years (inclusive) who opt for vaccination.
•Subjects who would receive GardasilÂ® according to the approved local prescribing information as per the Investigatorâ??s opinion.
•Subjects who the investigator believes that they or their parents/ guardians can and will comply with the requirements of the protocol.
•Subjects should own a phone so as to enable the investigator or qualified designee to call the subject for safety follow-up.

•Subjects having a history of known prior vaccination with a HPV vaccine prior to signing informed consent for participation in this surveillance
•Subjects who were previously enrolled in HPV vaccine surveillance and received a similar active agent or placebo.
•Subjects who have received any investigational product within 30 days prior to their first visit.
•Any condition which in the opinion of the investigator might interfere with the evaluation of the surveillance objectives.

发起方

MSD Pharmaceuticals PvtLtd